

Walter Maetzler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5241387/publications.pdf>

Version: 2024-02-01

297
papers

16,760
citations

19657

61
h-index

23533

111
g-index

324
all docs

324
docs citations

324
times ranked

22190
citing authors

#	ARTICLE	IF	CITATIONS
1	Peripheral neuropathy in Parkinson's disease: prevalence and functional impact on gait and balance. <i>Brain</i> , 2023, 146, 225-236.	7.6	11
2	Therapeutic climbing in Parkinson's disease: Differences in self-reported health and well-being, feasibility and clinical changes. <i>Physiotherapy Theory and Practice</i> , 2023, 39, 1163-1177.	1.3	4
3	Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?. <i>Age and Ageing</i> , 2022, 51, .	1.6	7
4	Functional Movement Disorder in Older Adults. <i>Current Clinical Neurology</i> , 2022, , 197-203.	0.2	2
5	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 783996.	3.4	13
6	Additive Effect of Dopaminergic Medication on Gait Under Single and Dual-Tasking Is Greater Than of Deep Brain Stimulation in Advanced Parkinson Disease With Long-duration Deep Brain Stimulation. <i>Neuromodulation</i> , 2022, , .	0.8	2
7	Reliability of IMU-Derived Temporal Gait Parameters in Neurological Diseases. <i>Sensors</i> , 2022, 22, 2304.	3.8	6
8	Fear of Falling Does Not Influence Dual-Task Gait Costs in People with Parkinson's Disease: A Cross-Sectional Study. <i>Sensors</i> , 2022, 22, 2029.	3.8	2
9	Postural Sway in Parkinson's Disease and Multiple Sclerosis Patients During Tasks With Different Complexity. <i>Frontiers in Neurology</i> , 2022, 13, 857406.	2.4	4
10	Improving functional disability in patients with tremor: A clinical perspective of the efficacies, considerations, and challenges of assistive technology. <i>Journal of the Neurological Sciences</i> , 2022, 435, 120197.	0.6	10
11	Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2022, , 1.	2.8	2
12	A Deep Learning Approach for Gait Event Detection from a Single Shank-Worn IMU: Validation in Healthy and Neurological Cohorts. <i>Sensors</i> , 2022, 22, 3859.	3.8	18
13	Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study. <i>EClinicalMedicine</i> , 2022, 51, 101549.	7.1	66
14	Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without Dementia. <i>Neurology</i> , 2021, 96, e904-e915.	1.1	9
15	Cognitive impairment and sedentary behavior predict health-related attrition in a prospective longitudinal Parkinson's disease study. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 37-43.	2.2	4
16	Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures. <i>Movement Disorders</i> , 2021, 36, 76-82.	3.9	31
17	Toward eScales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 208-214.	1.5	5
18	Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 963-976.	3.9	35

#	ARTICLE	IF	CITATIONS
19	Phenylalanine Effects on Brain Function in Adult Phenylketonuria. <i>Neurology</i> , 2021, 96, e399-e411.	1.1	29
20	Everyday Function in Alzheimer's and Parkinson's Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 197-209.	2.6	4
21	Effects of Levodopa on quality of sleep and nocturnal movements in Parkinson's Disease. <i>Journal of Neurology</i> , 2021, 268, 2506-2514.	3.6	11
22	The Mutation Matters: CSF Profiles of GCase, Sphingolipids, and Synuclein in PD_{GBA}. <i>Movement Disorders</i> , 2021, 36, 1216-1228.	3.9	40
23	Cerebellar rTMS in PSP: a Double-Blind Sham-Controlled Study Using Mobile Health Technology. <i>Cerebellum</i> , 2021, 20, 662-666.	2.5	11
24	Validation of IMU-based gait event detection during curved walking and turning in older adults and Parkinson's Disease patients. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2021, 18, 28.	4.6	39
25	Reliability of IMU-Derived Static Balance Parameters in Neurological Diseases. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3644.	2.6	14
26	Gait speed in clinical and daily living assessments in Parkinson's disease patients: performance versus capacity. <i>Npj Parkinson's Disease</i> , 2021, 7, 24.	5.3	44
27	Initial center of pressure position prior to anticipatory postural adjustments during gait initiation in people with Parkinson's disease with freezing of gait. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 8-14.	2.2	11
28	How COVID-19 will boost remote exercise-based treatment in Parkinson's disease: a narrative review. <i>Npj Parkinson's Disease</i> , 2021, 7, 25.	5.3	56
29	Step Length Is a Promising Progression Marker in Parkinson's Disease. <i>Sensors</i> , 2021, 21, 2292.	3.8	10
30	Age-related deterioration of performance and increase of cortex activity comparing time- versus item-controlled fNIRS measurement. <i>Scientific Reports</i> , 2021, 11, 6766.	3.3	3
31	Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1122-1131.	3.7	11
32	α-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2508-2518.	3.9	47
33	Short-term physical exercise impacts on the human holobiont obtained by a randomised intervention study. <i>BMC Microbiology</i> , 2021, 21, 162.	3.3	24
34	Comparison of Laboratory and Daily-Life Gait Speed Assessment during ON and OFF States in Parkinson's Disease. <i>Sensors</i> , 2021, 21, 3974.	3.8	13
35	A randomised controlled trial on effectiveness and feasibility of sport climbing in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 49.	5.3	4
36	Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease. <i>Annals of Neurology</i> , 2021, 90, E1-E12.	5.3	41

#	ARTICLE	IF	CITATIONS
37	Proposed Mobility Assessments with Simultaneous Full-Body Inertial Measurement Units and Optical Motion Capture in Healthy Adults and Neurological Patients for Future Validation Studies: Study Protocol. <i>Sensors</i> , 2021, 21, 5833.	3.8	16
38	The Power of Musification: Sensor-Based Music Feedback Improves Arm Swing in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1240-1247.	1.5	8
39	The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson's disease. <i>European Journal of Neurology</i> , 2021, 28, 1557-1565.	3.3	12
40	Gait and turning alterations in idiopathic REM sleep behavioral disorder and early Parkinson's disease: A cross-sectional study with mobile health technology. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119499.	0.6	0
41	Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes. <i>Npj Digital Medicine</i> , 2021, 4, 149.	10.9	54
42	Digital assessment at home – mPower against Parkinson disease. <i>Nature Reviews Neurology</i> , 2021, 17, 661-662.	10.1	6
43	Arm swing responsiveness to dopaminergic medication in Parkinson's disease depends on task complexity. <i>Npj Parkinson's Disease</i> , 2021, 7, 89.	5.3	14
44	Increased functional connectivity in a population at risk of developing Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 92, 1-6.	2.2	4
45	Autonomic Symptoms in Older Adults Are Common and Associated With Health-Related Quality of Life. <i>Frontiers in Neurology</i> , 2021, 12, 757748.	2.4	2
46	Active Magnetoelectric Motion Sensing: Examining Performance Metrics with an Experimental Setup. <i>Sensors</i> , 2021, 21, 8000.	3.8	4
47	Effect of Fear of Falling on Mobility Measured During Lab and Daily Activity Assessments in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 722830.	3.4	7
48	Technical validation of real-world monitoring of gait: a multicentric observational study. <i>BMJ Open</i> , 2021, 11, e050785.	1.9	56
49	Assessment of cognitive-driven activity of daily living impairment in non-demented Parkinson's patients. <i>Journal of Neuropsychology</i> , 2020, 14, 69-84.	1.4	17
50	Parkinson's Disease: <i>Glucocerebrosidase 1</i> Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles. <i>Movement Disorders</i> , 2020, 35, 495-499.	3.9	32
51	Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical Research. <i>Digital Biomarkers</i> , 2020, 3, 116-132.	4.4	30
52	Walking-related digital mobility outcomes as clinical trial endpoint measures: protocol for a scoping review. <i>BMJ Open</i> , 2020, 10, e038704.	1.9	29
53	Wearable Health Technology to Quantify the Functional Impact of Peripheral Neuropathy on Mobility in Parkinson's Disease: A Systematic Review. <i>Sensors</i> , 2020, 20, 6627.	3.8	9
54	Common diseases alter the physiological age-related blood microRNA profile. <i>Nature Communications</i> , 2020, 11, 5958.	12.8	46

#	ARTICLE	IF	CITATIONS
55	Insulin sensitivity predicts cognitive decline in individuals with prediabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001741.	2.8	42
56	Gait Analysis with Wearables Can Accurately Classify Fallers from Non-Fallers: A Step toward Better Management of Neurological Disorders. <i>Sensors</i> , 2020, 20, 6992.	3.8	24
57	Classification of Neurological Patients to Identify Fallers Based on Spatial-Temporal Gait Characteristics Measured by a Wearable Device. <i>Sensors</i> , 2020, 20, 4098.	3.8	19
58	Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential. <i>Neurotherapeutics</i> , 2020, 17, 1736-1746.	4.4	20
59	Quantification of Arm Swing during Walking in Healthy Adults and Parkinsonâ€™s Disease Patients: Wearable Sensor-Based Algorithm Development and Validation. <i>Sensors</i> , 2020, 20, 5963.	3.8	17
60	Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinsonâ€™s Disease Patients Using Digital Mobility Outcomes. <i>Sensors</i> , 2020, 20, 5920.	3.8	42
61	Distinct Relationship Between Cognitive Flexibility and White Matter Integrity in Individuals at Risk of Parkinsonâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 250.	3.4	3
62	Postural transitions detection and characterization in healthy and patient populations using a single waist sensor. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2020, 17, 70.	4.6	18
63	The detection of age groups by dynamic gait outcomes using machine learning approaches. <i>Scientific Reports</i> , 2020, 10, 4426.	3.3	29
64	Executive Function Is Related to the Urinary Urgency in Non-demented Patients With Parkinsonâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 55.	3.4	11
65	Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients. <i>JAMA Oncology</i> , 2020, 6, 714.	7.1	84
66	Does increased forefoot load contribute to freezing of gait in Parkinson's disease? A clinical observation. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 83-84.	2.2	1
67	Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment â€“ the ComOn-study. <i>BMC Geriatrics</i> , 2020, 20, 45.	2.7	19
68	Interrelation between Sarcopenia and the Number of Motor Neurons in Patients with Parkinsonian Syndromes. <i>Gerontology</i> , 2020, 66, 409-415.	2.8	19
69	Long-term unsupervised mobility assessment in movement disorders. <i>Lancet Neurology</i> , The, 2020, 19, 462-470.	10.2	181
70	Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1245-1248.	3.9	37
71	Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1233-1238.	3.9	22
72	Systematic Review Looking at the Use of Technology to Measure Free-Living Symptom and Activity Outcomes in Parkinsonâ€™s Disease in the Home or a Home-like Environment. <i>Journal of Parkinson's Disease</i> , 2020, 10, 429-454.	2.8	43

#	ARTICLE	IF	CITATIONS
73	Neurogeriatricsâ€”aâ€švision for improved care and research for geriatric patients with predominating neurological disabilities. Zeitschrift Fur Gerontologie Und Geriatrie, 2020, 53, 340-346.	1.8	10
74	Private variants in PRKN are associated with late-onset Parkinson's disease. Parkinsonism and Related Disorders, 2020, 75, 24-26.	2.2	4
75	Association of cognitive activities of daily living (ADL) function and nonmotor burden in nondemented Parkinsonâ€™s disease patients.. Neuropsychology, 2020, 34, 447-455.	1.3	7
76	Protocol for PD SENSORS: Parkinsonâ€™s Disease Symptom Evaluation in a Naturalistic Setting producing Outcome measuRes using SPHERE technology. An observational feasibility study of multi-modal multi-sensor technology to measure symptoms and activities of daily living in Parkinsonâ€™s disease. BMJ Open, 2020, 10, e041303.	1.9	15
77	Effects of Exergaming on Attentional Deficits and Dual-Tasking in Parkinson's Disease. Frontiers in Neurology, 2019, 10, 646.	2.4	15
78	Gait analysis with wearables predicts conversion to Parkinson disease. Annals of Neurology, 2019, 86, 357-367.	5.3	137
79	Mobility Deficits Assessed With Mobile Technology: What Can We Learn From Brain Iron-Altered Animal Models?. Frontiers in Neurology, 2019, 10, 833.	2.4	1
80	A combined miRNAâ€”piRNA signature to detect Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 250.	4.8	74
81	Reply to â€œQuantitative Motor Functioning in Prodromal Parkinson Diseaseâ€• Annals of Neurology, 2019, 86, 981-982.	5.3	0
82	Alterations in Blood Monocyte Functions in Parkinson's Disease. Movement Disorders, 2019, 34, 1711-1721.	3.9	67
83	Dual vs. Single Tasking During Circular Walking: What Better Reflects Progression in Parkinson's Disease?. Frontiers in Neurology, 2019, 10, 372.	2.4	6
84	Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network. Journal of Community Genetics, 2019, 10, 523-530.	1.2	10
85	Dementia with lewy bodies: <i>GBA1</i> mutations are associated with cerebrospinal fluid alphaâ€šsynuclein profile. Movement Disorders, 2019, 34, 1069-1073.	3.9	24
86	Functional movement disorders in neurogeriatric inpatients. Zeitschrift Fur Gerontologie Und Geriatrie, 2019, 52, 324-329.	1.8	10
87	A roadmap for implementation of patientâ€”centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. Movement Disorders, 2019, 34, 657-663.	3.9	213
88	The Parkinson's disease eâ€šdiary: Developing a clinical and research tool for the digital age. Movement Disorders, 2019, 34, 676-681.	3.9	43
89	Potential Markers of Progression in Idiopathic Parkinsonâ€™s Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study. Frontiers in Human Neuroscience, 2019, 13, 59.	2.0	27
90	Progressive Gait Deficits in Parkinsonâ€™s Disease: A Wearable-Based Biannual 5-Year Prospective Study. Frontiers in Aging Neuroscience, 2019, 11, 22.	3.4	45

#	ARTICLE	IF	CITATIONS
91	Machine Learning to Detect Alzheimer's Disease from Circulating Non-coding RNAs. <i>Genomics, Proteomics and Bioinformatics</i> , 2019, 17, 430-440.	6.9	67
92	Prodromal features of Parkinson's disease: Self-reported symptoms versus clinically assessed signs. <i>Movement Disorders</i> , 2019, 34, 144-146.	3.9	3
93	Fall Risk in Relation to Individual Physical Activity Exposure in Patients with Different Neurodegenerative Diseases: a Pilot Study. <i>Cerebellum</i> , 2019, 18, 340-348.	2.5	16
94	A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. <i>Journal of Parkinson's Disease</i> , 2019, 9, 31-61.	2.8	45
95	Parkinson's disease: evolution of cognitive impairment and CSF A β profiles in a prospective longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 165-170.	1.9	14
96	The Use of Virtual and Immersive Technology in Creating Personalized Multisensory Spaces for People Living With Dementia (SENSE-GARDEN): Protocol for a Multisite Before-After Trial. <i>JMIR Research Protocols</i> , 2019, 8, e14096.	1.0	10
97	Sarkopenie. , 2019, , 69-84.		2
98	Internationale Klassifikation der Funktionsfähigkeit, Behinderung und Gesundheit (ICF). , 2019, , 7-22.		0
99	The association between objectively measured physical activity, depression, cognition, and health-related quality of life in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 74-81.	2.2	35
100	Effect of physical activity on cognitive flexibility, depression and RBD in healthy elderly. <i>Clinical Neurology and Neurosurgery</i> , 2018, 165, 88-93.	1.4	26
101	Changing views after 200 years of Parkinson disease. <i>Nature Reviews Neurology</i> , 2018, 14, 70-72.	10.1	11
102	The wide genetic landscape of clinical frontotemporal dementia: systematic combined sequencing of 121 consecutive subjects. <i>Genetics in Medicine</i> , 2018, 20, 240-249.	2.4	60
103	Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. <i>Parkinsonism and Related Disorders</i> , 2018, 46, S53-S56.	2.2	63
104	miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease. <i>Oncotarget</i> , 2018, 9, 17455-17465.	1.8	94
105	Moderate Frequency Resistance and Balance Training Do Not Improve Freezing of Gait in Parkinson's Disease: A Pilot Study. <i>Frontiers in Neurology</i> , 2018, 9, 1084.	2.4	8
106	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 1123.	2.4	19
107	How Mobile Health Technology and Electronic Health Records Will Change Care of Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, S41-S45.	2.8	33
108	Biomarkers of Neurodegeneration in Autoimmune-Mediated Encephalitis. <i>Frontiers in Neurology</i> , 2018, 9, 668.	2.4	42

#	ARTICLE	IF	CITATIONS
109	Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson's disease diagnosis. PLoS ONE, 2018, 13, e0206536.	2.5	29
110	Validation of a Lower Back "Wearable"-Based Sit-to-Stand and Stand-to-Sit Algorithm for Patients With Parkinson's Disease and Older Adults in a Home-Like Environment. Frontiers in Neurology, 2018, 9, 652.	2.4	28
111	Wearables for gait and balance assessment in the neurological ward - study design and first results of a prospective cross-sectional feasibility study with 384 inpatients. BMC Neurology, 2018, 18, 114.	1.8	41
112	Deterioration of executive dysfunction in elderly with REM sleep behavior disorder (RBD). Neurobiology of Aging, 2018, 70, 242-246.	3.1	14
113	Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson's disease patients. Journal of Neurology, 2018, 265, 1976-1984.	3.6	7
114	Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease. Journal of Parkinson's Disease, 2018, 8, 455-462.	2.8	6
115	Are Hypometric Anticipatory Postural Adjustments Contributing to Freezing of Gait in Parkinson's Disease?. Frontiers in Aging Neuroscience, 2018, 10, 36.	3.4	54
116	Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease. Frontiers in Aging Neuroscience, 2018, 10, 51.	3.4	74
117	Effect of Fear of Falling on Turning Performance in Parkinson's Disease in the Lab and at Home. Frontiers in Aging Neuroscience, 2018, 10, 78.	3.4	35
118	Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?. Frontiers in Neurology, 2018, 9, 500.	2.4	45
119	Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring. Frontiers in Human Neuroscience, 2018, 12, 226.	2.0	47
120	Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2387-2395.	6.4	23
121	What is Functional Mobility Applied to Parkinson's Disease?. Journal of Parkinson's Disease, 2018, 8, 121-130.	2.8	39
122	Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease. Movement Disorders, 2018, 33, 1349-1353.	3.9	10
123	Arm swing asymmetry in overground walking. Scientific Reports, 2018, 8, 12803.	3.3	16
124	Cholinergic Pathway SNPs and Postural Control in 477 Older Adults. Frontiers in Aging Neuroscience, 2018, 10, 260.	3.4	1
125	Less Is More " Estimation of the Number of Strides Required to Assess Gait Variability in Spatially Confined Settings. Frontiers in Aging Neuroscience, 2018, 10, 435.	3.4	41
126	Inflammatory profile discriminates clinical subtypes in <i>LRRK2</i> -associated Parkinson's disease. European Journal of Neurology, 2017, 24, 427.	3.3	56

#	ARTICLE	IF	CITATIONS
127	The release and trans-synaptic transmission of Tau via exosomes. <i>Molecular Neurodegeneration</i> , 2017, 12, 5.	10.8	475
128	Home-Based Physical Behavior in Late Stage Parkinson Disease Dementia: Differences between Cognitive Subtypes. <i>Neurodegenerative Diseases</i> , 2017, 17, 135-144.	1.4	10
129	Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. <i>Movement Disorders</i> , 2017, 32, 1025-1034.	3.9	75
130	Global, Yet Incomplete Overview of Cohort Studies in Parkinson's disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 423-432.	2.8	25
131	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017, 38, 297-309.	2.5	87
132	Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. <i>Movement Disorders</i> , 2017, 32, 1780-1783.	3.9	19
133	Dementia with Lewy bodies. <i>NeuroReport</i> , 2017, 28, 1061-1065.	1.2	6
134	Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1401-1408.	3.9	91
135	Progression markers of motor deficits in Parkinson's disease: A biannual 4-year prospective study. <i>Movement Disorders</i> , 2017, 32, 1254-1256.	3.9	13
136	SNPs in A β clearance proteins. <i>Neurology</i> , 2017, 89, 2335-2340.	1.1	13
137	Is the Assessment of 5 Meters of Gait with a Single Body-Fixed-Sensor Enough to Recognize Idiopathic Parkinson's Disease-Associated Gait?. <i>Annals of Biomedical Engineering</i> , 2017, 45, 1266-1278.	2.5	23
138	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	3.1	12
139	Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia. <i>Neurodegenerative Diseases</i> , 2017, 17, 83-88.	1.4	23
140	Structural Ultrasound of the Medial Temporal Lobe in Alzheimer's Disease. <i>Ultraschall in Der Medizin</i> , 2017, 38, 294-300.	1.5	11
141	Associations between Early Markers of Parkinson's Disease and Sarcopenia. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 53.	3.4	39
142	Evidence for a Selectively Regulated Prioritization Shift Depending on Walking Situations in Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 75.	3.4	19
143	Gait Is Associated with Cognitive Flexibility: A Dual-Tasking Study in Healthy Older People. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 154.	3.4	26
144	White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 213.	3.4	12

#	ARTICLE	IF	CITATIONS
145	Algorithm for Turning Detection and Analysis Validated under Home-Like Conditions in Patients with Parkinson's Disease and Older Adults using a 6 Degree-of-Freedom Inertial Measurement Unit at the Lower Back. <i>Frontiers in Neurology</i> , 2017, 8, 135.	2.4	26
146	Validation of a Step Detection Algorithm during Straight Walking and Turning in Patients with Parkinson's Disease and Older Adults Using an Inertial Measurement Unit at the Lower Back. <i>Frontiers in Neurology</i> , 2017, 8, 457.	2.4	79
147	Dual-Task Performance in GBA Parkinson's Disease. <i>Parkinson's Disease</i> , 2017, 2017, 1-6.	1.1	2
148	No relevant association of kinematic gait parameters with Health-related Quality of Life in Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0176816.	2.5	19
149	Limited Effect of Dopaminergic Medication on Straight Walking and Turning in Early-to-Moderate Parkinson's Disease during Single and Dual Tasking. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 4.	3.4	23
150	Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 121.	3.4	16
151	Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 147.	3.4	33
152	Dual Tasking for the Differentiation between Depression and Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 235.	3.4	14
153	Cognitive Performance Patterns in Healthy Individuals with Substantia Nigra Hyperechogenicity and Early Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 271.	3.4	5
154	Inflammatory profile in LRRK2-associated prodromal and clinical PD. <i>Journal of Neuroinflammation</i> , 2016, 13, 122.	7.2	57
155	A Viewpoint on Wearable Technology-Enabled Measurement of Wellbeing and Health-Related Quality of Life in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 279-287.	2.8	40
156	Intra-Rater, Inter-Rater and Test-Retest Reliability of an Instrumented Timed Up and Go (iTUG) Test in Patients with Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0151881.	2.5	72
157	Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors. <i>PLoS ONE</i> , 2016, 11, e0150552.	2.5	31
158	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016, 31, 1272-1282.	3.9	464
159	Freezing of Swallowing. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 490-493.	1.5	11
160	Twelve-week sensor assessment in Parkinson's disease: Impact on quality of life. <i>Movement Disorders</i> , 2016, 31, 1337-1338.	3.9	20
161	A clinical view on the development of technology-based tools in managing Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1263-1271.	3.9	131
162	Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1270-1272.	1.9	65

#	ARTICLE	IF	CITATIONS
163	Motor dual-tasking deficits predict falls in Parkinson's disease: A prospective study. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 73-77.	2.2	92
164	Advances in sensor and wearable technologies for Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1257-1257.	3.9	17
165	Validation of conversion between mini-mental state examination and montreal cognitive assessment. <i>Movement Disorders</i> , 2016, 31, 593-596.	3.9	51
166	New methods for the assessment of Parkinson's disease (2005 to 2015): A systematic review. <i>Movement Disorders</i> , 2016, 31, 1283-1292.	3.9	119
167	Association of Plasma A β 40 Peptides, But Not A β 42, with Coronary Artery Disease and Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 161-169.	2.6	18
168	The FARSEEING real-world fall repository: a large-scale collaborative database to collect and share sensor signals from real-world falls. <i>European Review of Aging and Physical Activity</i> , 2016, 13, 8.	2.9	67
169	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 42.	6.2	14
170	Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. <i>Neuron</i> , 2016, 91, 56-66.	8.1	289
171	A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson's disease. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2016, 13, 24.	4.6	155
172	Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. <i>Movement Disorders</i> , 2016, 31, 742-747.	3.9	29
173	Validating Alzheimer's disease micro RNAs using next-generation sequencing. <i>Alzheimer's and Dementia</i> , 2016, 12, 565-576.	0.8	53
174	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016, 38, 214.e7-214.e10.	3.1	78
175	Health-Related Quality of Life in patients with Parkinson's disease – A systematic review based on the ICF model. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 61, 26-34.	6.1	144
176	Continuous leg dyskinesia assessment in Parkinson's disease – clinical validity and ecological effect. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 41-46.	2.2	36
177	Altered dendritic cell subset distribution in patients with Parkinson's disease: Impact of CMV serostatus. <i>Journal of Neuroimmunology</i> , 2016, 290, 60-65.	2.3	15
178	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. <i>American Journal of Human Genetics</i> , 2016, 98, 500-513.	6.2	333
179	In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. <i>Neurobiology of Disease</i> , 2016, 91, 59-68.	4.4	78
180	Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants. <i>Neurobiology of Aging</i> , 2016, 37, 208.e11-208.e17.	3.1	38

#	ARTICLE	IF	CITATIONS
181	Ambulatory Activity Components Deteriorate Differently across Neurodegenerative Diseases: A Cross-Sectional Sensor-Based Study. <i>Neurodegenerative Diseases</i> , 2016, 16, 317-323.	1.4	11
182	GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. <i>PLoS ONE</i> , 2016, 11, e0149349.	2.5	29
183	Quantitative Timed-Up-and-Go Parameters in Relation to Cognitive Parameters and Health-Related Quality of Life in Mild-to-Moderate Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0151997.	2.5	37
184	Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease. <i>Current Alzheimer Research</i> , 2016, 13, 654-662.	1.4	31
185	Clinical Parameters and Tools for Home-Based Assessment of Parkinson's Disease: Results from a Delphi study. <i>Journal of Parkinson's Disease</i> , 2015, 5, 281-290.	2.8	14
186	Association between vestibulo-ocular reflex suppression, balance, gait, and fall risk in ageing and neurodegenerative disease: protocol of a one-year prospective follow-up study. <i>BMC Neurology</i> , 2015, 15, 192.	1.8	15
187	Body-worn sensors-the brave new world of clinical measurement?. <i>Movement Disorders</i> , 2015, 30, 1203-1205.	3.9	25
188	Participatory Design in Parkinson's Research with Focus on the Symptomatic Domains to be Measured. <i>Journal of Parkinson's Disease</i> , 2015, 5, 187-196.	2.8	27
189	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	2.4	36
190	Digitomography in Parkinson's Disease: A Cross-Sectional and Longitudinal Study. <i>PLoS ONE</i> , 2015, 10, e0123914.	2.5	23
191	Progressive Supranuclear Palsy and Dementia. , 2015, , 147-157.		0
192	Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease - Report of the JPND Working Group BioLoC-PD. <i>Neuroepidemiology</i> , 2015, 45, 282-297.	2.3	23
193	Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2015, 36, 1072-1074.	3.1	34
194	<i>GBA</i> -associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study. <i>Movement Disorders</i> , 2015, 30, 407-411.	3.9	214
195	Reasons for mild parkinsonian signs - Which constellation may indicate neurodegeneration?. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 126-130.	2.2	15
196	The relation of SMI and the VSEP in a risk sample for neurodegenerative disorders. <i>Journal of Neural Transmission</i> , 2015, 122, 1167-1174.	2.8	8
197	Quantitative motor assessment of dyskinesias in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2015, 122, 1271-1278.	2.8	5
198	Gait velocity and step length at baseline predict outcome of Nordic walking training in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 413-416.	2.2	17

#	ARTICLE	IF	CITATIONS
199	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015, 11, 1306-1315.	0.8	104
200	Quantitative home-based assessment of Parkinson's symptoms: The SENSE-PARK feasibility and usability study. <i>BMC Neurology</i> , 2015, 15, 89.	1.8	71
201	Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1427-1434.	2.2	20
202	Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 32-37.	1.9	34
203	Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2015, 122, 419-425.	2.8	43
204	Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. <i>Molecular Psychiatry</i> , 2015, 20, 647-656.	7.9	235
205	Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer's disease. , 2015, 11, 465-474.		31
206	The Brain Response to Peripheral Insulin Declines with Age: A Contribution of the Blood-Brain Barrier?. <i>PLoS ONE</i> , 2015, 10, e0126804.	2.5	80
207	Age and Vascular Burden Determinants of Cortical Hemodynamics Underlying Verbal Fluency. <i>PLoS ONE</i> , 2015, 10, e0138863.	2.5	21
208	Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinson's Disease Patients and Controls. <i>PLoS ONE</i> , 2014, 9, e88604.	2.5	36
209	Risk for Femoral Fractures in Parkinson's Disease Patients with and without Severe Functional Impairment. <i>PLoS ONE</i> , 2014, 9, e97073.	2.5	33
210	Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson's Disease: Sources of (Error) Variance in Biomarker Assays. <i>PLoS ONE</i> , 2014, 9, e114566.	2.5	24
211	A Neurodegenerative Vascular Burden Index and the Impact on Cognition. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 161.	3.4	14
212	Instrumented Functional Reach Test Differentiates Individuals at High Risk for Parkinson's Disease from Controls. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 286.	3.4	18
213	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.	2.9	178
214	Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. <i>Movement Disorders</i> , 2014, 29, 479-487.	3.9	130
215	In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 α -synuclein antibody. <i>Acta Neuropathologica</i> , 2014, 128, 893-5.	7.7	8
216	Comment: Why do nondopaminergic features in Parkinson disease matter?. <i>Neurology</i> , 2014, 82, 417-417.	1.1	7

#	ARTICLE	IF	CITATIONS
217	Post-Cueing Deficits with Maintained Cueing Benefits in Patients with Parkinson's Disease Dementia. <i>Frontiers in Neurology</i> , 2014, 5, 236.	2.4	4
218	High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia. <i>Alzheimer's and Dementia</i> , 2014, 10, 530.	0.8	18
219	A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. <i>Movement Disorders</i> , 2014, 29, 470-478.	3.9	251
220	Prodromal features for Parkinson's disease – baseline data from the TREND study. <i>European Journal of Neurology</i> , 2014, 21, 766-772.	3.3	99
221	Technical and clinical view on ambulatory assessment in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 139-147.	2.1	49
222	A "bird's eye" view on the current status and potential benefits of blood biomarkers for Parkinson's disease. <i>Biomarkers in Medicine</i> , 2014, 8, 225-227.	1.4	13
223	Highly potent soluble amyloid- β^2 seeds in human Alzheimer brain but not cerebrospinal fluid. <i>Brain</i> , 2014, 137, 2909-2915.	7.6	61
224	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. <i>Nature Genetics</i> , 2014, 46, 989-993.	21.4	1,685
225	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2014, 128, 397-410.	7.7	93
226	Evidence for altered transport of insulin across the blood-brain barrier in insulin-resistant humans. <i>Acta Diabetologica</i> , 2014, 51, 679-681.	2.5	123
227	Mild Parkinsonian Signs in the Elderly – Is There an Association with PD? Cross-sectional Findings in 992 Individuals. <i>PLoS ONE</i> , 2014, 9, e92878.	2.5	25
228	Emerging therapies for gait disability and balance impairment: Promises and pitfalls. <i>Movement Disorders</i> , 2013, 28, 1576-1586.	3.9	50
229	Quantitative wearable sensors for objective assessment of Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1628-1637.	3.9	287
230	Development of a standard fall data format for signals from body-worn sensors. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2013, 46, 720-726.	1.8	22
231	Ageing-related cortical reorganization of verbal fluency processing: a functional near-infrared spectroscopy study. <i>Neurobiology of Aging</i> , 2013, 34, 439-450.	3.1	77
232	A Pan-European Study of the C9orf72 Repeat Associated with FTL D: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. <i>Human Mutation</i> , 2013, 34, 363-373.	2.5	247
233	The PRIPS study: screening battery for subjects at risk for Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 102-108.	3.3	113
234	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.8	344

#	ARTICLE	IF	CITATIONS
235	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , The, 2013, 12, 514-524.	10.2	126
236	SNCA: Major genetic modifier of age at onset of Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1217-1221.	3.9	36
237	Evaluation of Progression Markers in the Premotor Phase of Parkinson's Disease: The Progression Markers in the Premotor Phase Study. <i>Neuroepidemiology</i> , 2013, 41, 174-182.	2.3	20
238	No association of <i>GBA</i> mutations and multiple system atrophy. <i>European Journal of Neurology</i> , 2013, 20, e61-2.	3.3	28
239	Differentiation of Progressive Supranuclear Palsy: clinical, imaging and laboratory tools. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 362-370.	2.1	35
240	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2013, 70, 727.	9.0	374
241	Immune Profiling in Blood Identifies sTNF-R1 Performing Comparably Well as Biomarker Panels for Classification of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 367-375.	2.6	19
242	Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study. <i>PLoS ONE</i> , 2013, 8, e73094.	2.5	176
243	Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia. <i>International Journal of Alzheimer's Disease</i> , 2013, 2013, 1-2.	2.0	0
244	Altered Serum IgG Levels to α -Synuclein in Dementia with Lewy Bodies and Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e64649.	2.5	31
245	Clinical Characteristics with an Impact on ADL Functions of PD Patients with Cognitive Impairment Indicative of Dementia. <i>PLoS ONE</i> , 2013, 8, e82902.	2.5	10
246	Longitudinal Changes of Nerve Conduction Velocity, Distal Motor Latency, Compound Motor Action Potential Duration, and Skin Temperature During Prolonged Exposure to Cold in a Climate Chamber. <i>International Journal of Neuroscience</i> , 2012, 122, 528-531.	1.6	6
247	S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF- α pathway. <i>Brain</i> , 2012, 135, 3336-3347.	7.6	159
248	Lowered Serum Amyloid- β 1-42 Autoantibodies in Individuals with Lifetime Depression. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 95-100.	2.6	9
249	Reply: Presyndromic phase: Proposal for a new term for an emerging concept. <i>Movement Disorders</i> , 2012, 27, 1584-1585.	3.9	0
250	Vorschlag für ein Mehrphasensturzmodell auf der Basis von Sturzdokumentationen mit am Körper getragenen Sensoren. <i>Zeitschrift Für Gerontologie Und Geriatrie</i> , 2012, 45, 707-715.	1.8	50
251	Using multi-dimensional dynamic time warping for TUG test instrumentation with inertial sensors. , 2012, , .		13
252	Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. <i>Neurobiology of Aging</i> , 2012, 33, 2949.e13-2949.e17.	3.1	86

#	ARTICLE	IF	CITATIONS
253	Protein Clearance Mechanisms of Alpha-Synuclein and Amyloid-Beta in Lewy Body Disorders. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-9.	2.0	31
254	Motor signs in the prodromal phase of Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 627-633.	3.9	78
255	Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsy-parkinsonism. <i>Movement Disorders</i> , 2012, 27, 151-155.	3.9	31
256	Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 288-293.	3.9	19
257	Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. <i>Journal of Neural Transmission</i> , 2012, 119, 39-52.	2.8	68
258	Impaired Trunk Stability in Individuals at High Risk for Parkinson's Disease. <i>PLoS ONE</i> , 2012, 7, e32240.	2.5	79
259	Serum and Cerebrospinal Fluid Levels of Transthyretin in Lewy Body Disorders with and without Dementia. <i>PLoS ONE</i> , 2012, 7, e48042.	2.5	23
260	Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid β deposition. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1060-1062.	1.9	22
261	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , 2011, 43, 699-705.	21.4	502
262	Autoantibodies Against Amyloid and Glial-Derived Antigens are Increased in Serum and Cerebrospinal Fluid of Lewy Body-Associated Dementias. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 171-179.	2.6	55
263	Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. <i>Neurobiology of Aging</i> , 2011, 32, 1599-1606.	3.1	40
264	Influence of Different Cut-Off Values on the Diagnosis of Mild Cognitive Impairment in Parkinson's Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-7.	1.1	31
265	Poor Trail Making Test Performance Is Directly Associated with Altered Dual Task Prioritization in the Elderly - Baseline Results from the TREND Study. <i>PLoS ONE</i> , 2011, 6, e27831.	2.5	78
266	Serum and Cerebrospinal Fluid Uric Acid Levels in Lewy Body Disorders: Associations with Disease Occurrence and Amyloid- β Pathway. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 119-126.	2.6	40
267	In vivo comparison of Richardson's syndrome and progressive supranuclear palsy-parkinsonism. <i>Journal of Neural Transmission</i> , 2011, 118, 1191-1197.	2.8	30
268	Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. <i>Movement Disorders</i> , 2011, 26, 176-181.	3.9	43
269	Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. <i>Movement Disorders</i> , 2011, 26, 2335-2342.	3.9	65
270	Comparison of acceleration signals of simulated and real-world backward falls. <i>Medical Engineering and Physics</i> , 2011, 33, 368-373.	1.7	127

#	ARTICLE	IF	CITATIONS
271	Serum Insulinlike Growth Factor 1 as Possible Marker for Risk and Early Diagnosis of Parkinson Disease. Archives of Neurology, 2011, 68, 925.	4.5	45
272	Decreased α -Synuclein Serum Levels in Patients with Lewy Body Dementia Compared to Alzheimer's Disease Patients and Control Subjects. Dementia and Geriatric Cognitive Disorders, 2011, 31, 413-416.	1.5	35
273	Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease. Archives of Neurology, 2011, 68, 932.	4.5	146
274	Improvement of balance after audio-biofeedback. Zeitschrift Fur Gerontologie Und Geriatrie, 2010, 43, 224-228.	1.8	36
275	Clinical and dual-tasking aspects in frequent and infrequent fallers with progressive supranuclear palsy. Movement Disorders, 2010, 25, 1040-1046.	3.9	25
276	Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Movement Disorders, 2010, 25, 1464-1469.	3.9	45
277	Neprilysin Activity in Cerebrospinal Fluid is Associated with Dementia and Amyloid- β 42 Levels in Lewy Body Disease. Journal of Alzheimer's Disease, 2010, 22, 933-938.	2.6	23
278	The human G93A SOD1 phenotype closely resembles sporadic amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 764-767.	1.9	25
279	Macrophage Colony-Stimulating Factor (M-CSF) in Plasma and CSF of Patients with Mild Cognitive Impairment and Alzheimers Disease. Current Alzheimer Research, 2010, 7, 409-414.	1.4	36
280	Progressive Secondary Neurodegeneration and Microcalcification Co-Occur in Osteopontin-Deficient Mice. American Journal of Pathology, 2010, 177, 829-839.	3.8	22
281	The CST3 BB Genotype and Low Cystatin C Cerebrospinal Fluid Levels are Associated with Dementia in Lewy Body Disease. Journal of Alzheimer's Disease, 2010, 19, 937-942.	2.6	32
282	Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiology of Disease, 2009, 34, 107-112.	4.4	177
283	No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiology of Disease, 2009, 35, 296-301.	4.4	15
284	Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurology, The, 2009, 8, 1158-1171.	10.2	261
285	Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration" [¹⁸ F]FDG-PET. Movement Disorders, 2009, 24, 1504-1511.	3.9	46
286	A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. Journal of Neural Transmission, 2009, 116, 599-605.	2.8	16
287	Microcalcification after excitotoxicity is enhanced in transgenic mice expressing parvalbumin in all neurones, may commence in neuronal mitochondria and undergoes structural modifications over time. Neuropathology and Applied Neurobiology, 2009, 35, 165-177.	3.2	21
288	Glial Cell-Line Derived Neurotrophic Factor (GDNF) Concentrations in Cerebrospinal Fluid and Serum of Patients with Early Alzheimer's Disease and Normal Controls. Journal of Alzheimer's Disease, 2009, 18, 331-337.	2.6	72

#	ARTICLE	IF	CITATIONS
289	[11C]PIB binding in Parkinson's disease dementia. <i>NeuroImage</i> , 2008, 39, 1027-1033.	4.2	133
290	Treatment of Dementia in Parkinsonian Syndromes with Cholinesterase Inhibitors. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 351-367.	1.5	11
291	Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. <i>Neurobiology of Disease</i> , 2007, 25, 473-482.	4.4	111
292	BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. <i>Journal of Psychiatric Research</i> , 2007, 41, 387-394.	3.1	249
293	GABAB receptor expression and cellular localization in gerbil hippocampus after transient global ischemia. <i>Neuroscience Letters</i> , 2006, 395, 118-123.	2.1	23
294	Ectopic parvalbumin expression in mouse forebrain neurons increases excitotoxic injury provoked by ibotenic acid injection into the striatum. <i>Experimental Neurology</i> , 2004, 186, 78-88.	4.1	30
295	The Role of Mobility Endpoints in Marketing Authorisation of Drugs; What Gets the EMA Moving?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
296	Static Balance and Chair-Rise Performance in Neurogeriatric Patients: Promising Short Physical Performance Battery-Derived Predictors of Fear of Falling. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	0
297	Reply: Vitamins B6 and B12, levodopa, and their complex interactions in patients with Parkinson's disease. <i>Brain</i> , 0, , .	7.6	2